145 related articles for article (PubMed ID: 12810202)
1. A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer.
Samant RS; Dunscombe PB; Roberts GH
Urol Oncol; 2003; 21(3):171-7. PubMed ID: 12810202
[TBL] [Abstract][Full Text] [Related]
2. Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer.
Neymark N; Adriaenssen I; Gorlia T; Caleo S; Bolla M
Health Econ; 2002 Apr; 11(3):233-48. PubMed ID: 11921320
[TBL] [Abstract][Full Text] [Related]
3. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
Konski A; Watkins-Bruner D; Brereton H; Feigenberg S; Hanks G
Cancer; 2006 Jan; 106(1):51-7. PubMed ID: 16323171
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysis.
Neymark N; Adriaenssen I; Gorlia T; Caleo S; Bolla M; Brochon D
Eur J Cancer; 2001 Sep; 37(14):1768-74. PubMed ID: 11549430
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer.
Cheng TF; Wang JD; Uen WC
BMC Cancer; 2012 Jan; 12():33. PubMed ID: 22264299
[TBL] [Abstract][Full Text] [Related]
6. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
Bolla M; Gonzalez D; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Gil T; Collette L; Pierart M
N Engl J Med; 1997 Jul; 337(5):295-300. PubMed ID: 9233866
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials.
Bolla M; de Reijke TM; Zurlo A; Collette L
Front Radiat Ther Oncol; 2002; 36():81-6. PubMed ID: 11842758
[No Abstract] [Full Text] [Related]
8. Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis.
Nygård R; Norum J; Due J
Anticancer Res; 2001; 21(1B):781-8. PubMed ID: 11299844
[TBL] [Abstract][Full Text] [Related]
9. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.
Hanks GE; Pajak TF; Porter A; Grignon D; Brereton H; Venkatesan V; Horwitz EM; Lawton C; Rosenthal SA; Sandler HM; Shipley WU;
J Clin Oncol; 2003 Nov; 21(21):3972-8. PubMed ID: 14581419
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer.
Akaza H
BJU Int; 2004 Jan; 93(1):42-6. PubMed ID: 14678365
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy.
Iannazzo S; Pradelli L; Carsi M; Perachino M
Value Health; 2011 Jan; 14(1):80-9. PubMed ID: 21211489
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer--the therapeutic challenge of locally advanced disease.
Blasko JC; Lange PH
N Engl J Med; 1997 Jul; 337(5):340-1. PubMed ID: 9233872
[No Abstract] [Full Text] [Related]
14. [Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials].
Noël G; Mazeron JJ
Cancer Radiother; 2001 Apr; 5(2):205. PubMed ID: 11355590
[No Abstract] [Full Text] [Related]
15. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.
Pilepich MV; Caplan R; Byhardt RW; Lawton CA; Gallagher MJ; Mesic JB; Hanks GE; Coughlin CT; Porter A; Shipley WU; Grignon D
J Clin Oncol; 1997 Mar; 15(3):1013-21. PubMed ID: 9060541
[TBL] [Abstract][Full Text] [Related]
16. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10).
Konski A; Sherman E; Krahn M; Bremner K; Beck JR; Watkins-Bruner D; Pilepich M
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):788-94. PubMed ID: 16109464
[TBL] [Abstract][Full Text] [Related]
17. Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
Pollack A; Horwitz EM
Nat Clin Pract Oncol; 2005 Jan; 2(1):12-3. PubMed ID: 16264846
[No Abstract] [Full Text] [Related]
18. Neoadjuvant hormonal treatment and radiotherapy for prostate cancer.
Wachter S; Wachter-Gerstner N; Pötter R
Oncology; 2003; 65 Suppl 1():29-33. PubMed ID: 12949431
[TBL] [Abstract][Full Text] [Related]
19. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.
Pilepich MV; Winter K; Lawton CA; Krisch RE; Wolkov HB; Movsas B; Hug EB; Asbell SO; Grignon D
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1285-90. PubMed ID: 15817329
[TBL] [Abstract][Full Text] [Related]
20. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy.
Horwitz EM; Winter K; Hanks GE; Lawton CA; Russell AH; Machtay M
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):947-56. PubMed ID: 11240235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
